Image
Webcast

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Meeting Slides

Clinical Practice Guidelines

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.

Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services 

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV Resources

National Institutes of Health

Suggested Readings

Drug utilization review.

Academy of Managed Care Pharmacy.

Long-acting injectables: current perspectives and future promise.

Chaudhary K, Patel MM, Mehta PJ. Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181.

Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults.

McGowan JP, Fine SM, Vail RM, et al. Baltimore (MD): Johns Hopkins University; 2022.

Lenacapavir as part of a combination regimen in treatment-naïve people with HIV: Week 54 results.

Gupta SK, Sims J, Brinson C, et al. Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine.

Johnson K, Sawkin MT. Drugs Context. 2022;11:2021-9-2.

ASHP statement on advocacy as a professional obligation.

Little J, Ortega M, Powell M, Hamm M. Am J Health Syst Pharm. 2019;76(4):251-253.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Llibre JM, Hung CC, Brinson C, et al. Lancet. 2018;391(10123):839-849.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. 

Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. 

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. 

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

HIV and ischemic heart disease.

Vachiat A, McCutcheon K, Tsabedze N, et al. J Am Coll Cardiol. 2017;69(1):73-82.

Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.

van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020;71(8):1920-1929.

Activity
Activity for event:Assessing Pros and Cons of ART Regimens

How to Counsel Your HIV Patients as Treatment Choices Expand

Activity
Activity for event:A Patient-Centered Approach to HIV Management

What the Pharmacist Needs to Know to Optimize ART Regimens

Activity
Activity for event:Assessing Pros and Cons of ART Regimens

How to Counsel Your HIV Patients as Treatment Choices Expand

Activity
Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice

BRIDGE PrEP

Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care